Influence of hydroxychloroquine on the bioavailability of oral metoprolol

British Journal of Clinical Pharmacology

Volumn 49, Issue 6, 2000, Pages 549-554

  Somer, Mika ^a   Kallio, Jaana ^a   Pesonen, Ullamari ^a   Pyykkö, Kaija ^a   Huupponen, Risto ^a   Scheinin, Mika ^a  

^a UNIVERSITY OF TURKU   (Finland)

Author keywords

CYP2D6; Dextromethorphan (DM); Hydroxychloroquine (HCQ); Interaction; Metoprolol

Indexed keywords

CHLOROQUINE; CYTOCHROME P450 2D6; DEBRISOQUINE; DEXTROMETHORPHAN; DRUG METABOLIZING ENZYME; HYDROXYCHLOROQUINE; ISOENZYME; LAGUN; METOPROLOL; PLACEBO; QUINIDINE; SPESICOR; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG METABOLISM; HUMAN; MALE; MUTATION; NORMAL HUMAN; PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADRENERGIC BETA-ANTAGONISTS; ADULT; ANTIMALARIALS; ANTIRHEUMATIC AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP2D6; DEXTROMETHORPHAN; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; HALF-LIFE; HUMANS; HYDROXYCHLOROQUINE; MALE; METOPROLOL;

EID: 0034030909     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2000.00197.x     Document Type: Article

References (36)

1. 1 Tett S, Cutler D, Day R. Antimalarials in rheumatic diseases. Baillieres Clin Rheumatol 1990; 4: 467-489.
2. 2 Tett SE. Clinical pharmacokinetics of slow-acting antirheumatic drugs. Clin Pharmacokinet 1993; 25: 392-407.
3. 3 Brocks DR, Skeith KJ, Johnston C, et al. Hematologic disposition of hydroxychloroquine enantiomers. J Clin Pharmacol 1994; 34: 1088-1097.
4. 4 Tett SE, Cutler DJ, Day RO, Brown KF. Bioavailability of hydroxychloroquine tablets in healthy volunteers. Br J Clin Pharmacol 1989; 27: 771-779.
5. 5 Touw DJ. Clinical implications of genetic polymorphisms and drug interactions mediated by cytochrome P-450 enzymes. Drug Metabol Drug Interact 1997; 14: 55-82.
6. 6 Lancaster DL, Adio RA, Tai KK, et al. Inhibition of metoprolol metabolism by chloroquine and other antimalarial drugs. J Pharm Pharmacol 1990; 42: 267-271.
7. 7 Masimirembwa CM, Hasler JA, Johansson I. Inhibitory effects of antiparasitic drugs on cytochrome P450 2D6. Eur J Clin Pharmacol 1995; 48: 35-38.
8. 8 Masimirembwa CM, Gustafsson LL, Dahl ML, Abdi YA, Hasler JA. Lack of effect of chloroquine on the debrisoquine (CYP2D6) and S-mephenytoin (CYP2C19) hydroxylation phenotypes. Br J Clin Pharmacol 1996; 41: 344-346.
9. 9 Adedoyin A, Frye RF, Mauro K, Branch RA. Chloroquine modulation of specific metabolizing enzymes activities: investigation with selective five drug cocktail. Br J Clin Pharmacol 1998; 46: 215-219.
10. 10 Otton SV, Inaba T, Kalow W. Competitive inhibition of sparteine oxidation in human liver by beta-adrenoceptor antagonists and other cardiovascular drugs. Life Sci 1984; 34: 73-80.
11. 11 Mikus G, Ha HR, Vozeh S, Zekorn C, Follath F, Eichelbaum M. Pharmacokinetics and metabolism of quinidine in extensive and poor metabolisers of sparteine. Eur J Clin Pharmacol 1986; 31: 69-72.
12. 12 Hildebrand M, Seifert W, Reichenberger A. Determination of dextromethorphan metabolizer phenotype in healthy volunteers. Eur J Clin Pharmacol 1989; 36: 315-318.
13. 13 Schmid B, Bircher J, Preisig R, Kupfer A. Polymorphic dextromethorphan metabolism: co-segregation of oxidative O-demethylation with debrisoquin hydroxylation. Clin Pharmacol Ther 1985; 38: 618-624.
14. 14 Horai Y, Nakano M, Ishizaki T, et al. Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese. Clin Pharmacol Ther 1989; 46: 198-207.
15. 15 Iyun AO, Lennard MS, Tucker GT, Woods HF. Metoprolol and debrisoquin metabolism in Nigerians: lack of evidence for polymorphic oxidation. Clin Pharmacol Ther 1986; 40: 387-394.
16. 16 Chladek J, Zimova G, Martinkova J, Tuma I. Intra-individual variability and influence of urine collection period on dextromethorphan metabolic ratios in healthy subjects. Fundam Clin Pharmacol 1999; 13: 508-515.
17. 17 Evans WE, Relling MV, Petros WP, Meyer WH, Mirro J Jr, Crom WR. Dextromethorphan and caffeine as probes for simultaneous determination of debrisoquin-oxidation and N-acetylation phenotypes in children. Clin Pharmacol Ther 1989; 45: 568-573.
18. 18 Neuvonen PJ, Kivistö KT, Laine K, Pyykkö K. Prevention of chloroquine absorption by activated charcoal. Hum Exp Toxicol 1992; 11: 117-120.
19. 19 Roivas L, Ojala-Karlsson P, Neuvonen PJ. The bioavailability of two beta-blockers preadsorbed onto charcoal. Meth Find Exp Clin Pharmacol 1994; 16: 125-132.
20. 20 Heim M, Meyer UA. Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. Lancet 1990; 336: 529-532.
21. 21 Wood AJ. Ethnic differences in drug disposition and response. Ther Drug Monit 1998; 20: 525-526.
22. 22 Bertilsson L. Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Clin Pharmacokinet 1995; 29: 192-209.
23. 23 Broly F, Gaedigk A, Heim M, Eichelbaum M, Morike K, Meyer UA. Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population. DNA Cell Biol 1991; 10: 545-558.
24. 24 Marez D, Legrand M, Sabbagh N, et al. Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics 1997; 7: 193-202.
25. 25 Borg KO, Carlsson E, Hoffmann KJ, Jonsson TE, Thorin H, Wallin B. Metabolism of metoprolol-(3-h) in man, the dog and the rat. Acta Pharmacol Toxicol 1975; 36: 125-135.
26. 26 Johnson JA, Burlew BS. Metoprolol metabolism via cytochrome P4502D6 in ethnic populations. Drug Metab Dispos 1996; 24: 350-355.
27. 27 Lennard MS, Silas JH, Freestone S, Ramsay LE, Tucker GT, Woods HF. Oxidation phenotype - a major determinant of metoprolol metabolism and response. N Engl J Med 1982; 307: 1558-1560.
28. 28 Lennard MS, Tucker GT, Woods HF, Silas JH, Iyun AO. Stereoselective metabolism of metoprolol in Caucasians and Nigerians - relationship to debrisoquine oxidation phenotype. Br J Clin Pharmacol 1989; 27: 613-616.
29. 29 Koytchev R, Alken RG, Vlahov V, et al. Influence of the cytochrome P4502D6*4 allele on the pharmacokinetics of controlled-release metoprolol. Eur J Clin Pharmacol 1998; 54: 469-474.
30. 30 Hartter S, Dingemanse J, Baier D, Ziegler G, Hiemke C. Inhibition of dextromethorphan metabolism by moclobemide. Psychopharmacology 1998; 135: 22-26.
31. 31 Capon DA, Bochner F, Kerry N, Mikus G, Danz C, Somogyi AA. The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans. Clin Pharmacol Ther 1996; 60: 295-307.
32. 32 Abdel-Rahman SM, Marcucci K, Boge T, Gotschall RR, Kearns GL, Leeder JS. Potent inhibition of cytochrome P-450 2D6-mediated dextromethorphan O-demethylation by terbinafine. Drug Metab Dispos 1999; 27: 770-775.
33. 33 Martinez C, Albet C, Agundez JA, et al. Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2-receptor antagonists. Clin Pharmacol Ther 1999; 65: 369-376.
34. 34 Ozdemir V, Naranjo CA, Shulman RW, et al. Determinants of interindividual variability and extent of CYP2D6 and CYP1A2 inhibition by paroxetine and fluvoxamine in vivo. J Clin Psychopharmacol 1998; 18: 198-207.
35. 35 von Moltke LL, Greenblatt DJ, Grassi JM, et al. Multiple human cytochromes contribute to biotransformation of dextromethorphan in vitro: role of CYP2C9, CYP2C19, CYP2D6, and CYP3A. Clin Pharmacol Ther 1998; 50: 997-1004.
36. 36 Panserat S, Sica L, Gerard N, Mathieu H, Jacqz-Aigrain E, Krishnamoorthy R. CYP2D6 polymorphism in a Gabonese population: contribution of the CYP2D6*2 and CYP2D6*17 alleles to the high prevalence of the intermediate metabolic phenotype. Br J Clin Pharmacol 1999; 47: 121-124.